

Isoray, Inc. and Subsidiaries
Consolidated Balance Sheets (Unaudited)
(In thousands, except shares)

	<u>September 30,</u> <u>2020</u>	<u>June 30,</u> <u>2020</u>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,940	\$ 2,392
Accounts receivable, net	1,758	2,044
Inventory	641	645
Prepaid expenses and other current assets	407	426
	<hr/>	<hr/>
Total current assets	4,746	5,507
Property and equipment, net	1,814	1,735
Right of use asset	951	1,001
Restricted cash	182	181
Inventory, non-current	204	137
Other assets, net	128	138
	<hr/>	<hr/>
Total assets	<u>\$ 8,025</u>	<u>\$ 8,699</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable and accrued expenses	\$ 758	\$ 654
Lease liability	241	236
Accrued protocol expense	91	35
Accrued radioactive waste disposal	100	94
Accrued payroll and related taxes	110	352
Accrued vacation	222	204
	<hr/>	<hr/>
Total current liabilities	1,522	1,575
Long-term liabilities:		
Lease liability, non-current	715	769
Accrued payroll and related taxes, non-current	108	55
Asset retirement obligation	585	577
	<hr/>	<hr/>
Total liabilities	2,930	2,976
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$.001 par value; 7,000,000 shares authorized: Series B: 5,000,000		
shares allocated; 59,065 shares issued and outstanding	-	-
Common stock, \$.001 par value; 200,000,000 shares authorized; 68,897,779 and 68,897,779 shares issued and outstanding	69	69
Treasury stock	-	-
Additional paid-in capital	93,677	93,592
Accumulated deficit	(88,651)	(87,938)
	<hr/>	<hr/>
Total stockholders' equity	5,095	5,723
	<hr/>	<hr/>
Total liabilities and stockholders' equity	<u>\$ 8,025</u>	<u>\$ 8,699</u>

Isoray, Inc. and Subsidiaries
Consolidated Statements of Operations (Unaudited)
(Dollars and shares in thousands, except for per-share amounts)

	Quarter ended September 30,	
	2020	2019
Sales, net	\$ 2,384	\$ 2,315
Cost of sales	<u>1,138</u>	<u>1,079</u>
Gross profit	<u>1,246</u>	<u>1,236</u>
Operating expenses:		
Research and development		
Propriety research and development	312	233
Collaboration arrangement, net of reimbursement	-	-
Total research and development	<u>312</u>	<u>233</u>
Sales and marketing	581	815
General and administrative	1,067	1,097
Change in estimate of asset retirement obligation (Note 9)	-	(73)
Total operating expenses	<u>1,960</u>	<u>2,072</u>
Operating loss	<u>(714)</u>	<u>(836)</u>
Non-operating income:		
Interest income, net	1	20
Change in fair value of warrant derivative liability	-	-
Other income	-	-
Non-operating income, net	<u>1</u>	<u>20</u>
Net loss	(713)	(816)
Preferred stock dividends	<u>(3)</u>	<u>(3)</u>
Net loss applicable to common stockholders	<u>(716)</u>	<u>(819)</u>
Basic and diluted loss per share	<u>\$ (0.01)</u>	<u>\$ (0.01)</u>
Weighted average shares used in computing net loss per share:		
Basic and diluted	<u>68,898</u>	<u>67,388</u>